Lupus
Advanced MRI finds brain abnormalities linked to cognitive dysfunction in lupus
Advanced structural MRI can detect brain abnormalities linked with cognitive dysfunction in patients with systemic lupus erythematosus, according to a systematic review published in Lupus Science & Medicine.
Newly illuminated molecular roots of lupus may lead to treatments with ‘durable benefits’
A recent investigation into the molecular roots of systemic lupus erythematosus may point the way toward a new generation of therapeutic targets, according to the researchers.
Zetomipzomib trial in lupus nephritis paused after four patient deaths
Kezar Life Sciences has paused a phase 2b trial of zetomipzomib in active lupus nephritis after reporting four patient deaths, according to a press release from the manufacturer.
'I am optimistic': Lupus pipeline features promising B-cell depletion therapies
SAN DIEGO — Obinutuzumab and ianalumab are two promising B-cell depleting therapies on the horizon for lupus, according to data presented at the 2024 Congress of Clinical Rheumatology West.
Dapirolizumab pegol achieves clinical improvement in moderate-to-severe lupus
Dapirolizumab pegol met its primary endpoint, achieving clinical improvement, when combined with standard-of-care treatment for moderate-to-severe systemic lupus erythematosus, according to topline results announced by its manufacturers.
Among herbal supplements, elderberry poses greatest risks in autoimmune skin disease
Use of elderberry as an herbal supplement preceded disease exacerbation in 62% of patients with dermatomyositis, and in 50% of those with cutaneous lupus erythematosus, according to data published in ACR Open Rheumatology.
Anti-Ro antibodies in lupus portend higher disease activity, steroid use
Patients with systemic lupus erythematosus who are positive for anti-Ro60 or anti-Ro52 antibodies may face higher disease activity and more intensive treatment needs, according to data published in Rheumatology.
New organ damage more common in lupus’ early stages; musculoskeletal system most impacted
Most new organ damage in systemic lupus erythematosus occurs in the first year after diagnosis, with the greatest impacts reported in the cardiovascular and musculoskeletal systems, according to data published in Lupus Science & Medicine.
Shared decision-making boosts trust in physicians among patients with lupus
Practicing shared decision-making increases overall trust in health care providers among patients with systemic lupus erythematosus, according to data published in Arthritis Care & Research.
FDA fast tracks CAR T-cell therapy for refractory lupus in anticipation of phase 1 trial
The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.